论文部分内容阅读
一些报道提出,大剂量静脉内 IgG(IVIG)治疗可能有益于膜性或狼疮性肾炎所致的肾病综合征病人。除间接作用于免疫调节机理外,IgG 还可在免疫沉淀的直接分解方面有作用。为评价这些初步结果,作者进行了一项大剂量 IVIG 治疗肾小球肾炎病人的公开试验。对6例临床肾病病人(尿蛋白丢失>3.5g/24h)进行了研究,肾小球肾炎经肾活检诊断。给予病人静脉输注 IgG 0.4g/kg/d,10小时内输完,连续5天,1～2月后重复一次。输注时和输注后评价病人的尿蛋白、尿沉淀、肾功能、血浆蛋白、血脂和各种免疫学变数。第3例病人有肾功能损害,第一疗程末肌酐突
Some reports suggest that high-dose intravenous IgG (IVIG) may benefit the nephrotic syndrome caused by membranous or lupus nephritis. In addition to acting indirectly on the immunomodulatory mechanism, IgG can also play a role in the direct breakdown of immunoprecipitations. To assess these preliminary results, the authors conducted a public trial of high-dose IVIG in patients with glomerulonephritis. Six patients with clinical nephropathy (urinary protein loss> 3.5g / 24h) were studied, and glomerulonephritis was diagnosed by renal biopsy. Patients given intravenous IgG 0.4g / kg / d, lose within 10 hours, 5 consecutive days, 1 to 2 months after the repeat. The patient’s urine protein, urine sediment, renal function, plasma proteins, lipids, and various immunological variables were evaluated during and after infusion. The third case of patients with renal dysfunction, creatinine sudden end of the first course of treatment